NCT03100903View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

January 10, 2018

Study Completion Date

January 10, 2018

Conditions
Healthy
Interventions
DRUG

BI 655130

single dose

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY